[1]https://www.onclive.com/view/antibody-drug-conjugates-expand-her2-breast-cancer-treatment-options [2]DS-8201a in pre-treated HER2 breast cancer that cannot be surgically removed or has spread [DESTINY-Breast02]. ClinicalTrials.gov. Updated August 12, 2022. Accessed November 28, 2022. [3...
[3] Galanti D, Inno A, La Vecchia M, et al. Current treatment options for HER2-positive breast cancer patients with brain metastases. Crit Rev Oncol Hematol. 2021 May;161:103329. [4] Garcia-Alvarez A, Papakonstantinou A, Oliveira M. Br...
乳腺癌是引起脑转移瘤的第二大常见原因,占所有脑转移的15%～20%[1],晚期乳腺癌脑转移(breast cancer brain metastases,BCBM)的比例为10%-15%[2],约0.4%-4.3%的乳腺癌患者初诊时即伴有脑转移[3]。脑转移对乳腺癌患者的生存质量...
Brain metastases (BMs) are frequently associated with HER2+ breast cancer (BC). Their management is based on a multi-modal strategy including both local treatment and systemic therapy. Despite therapeutic advance, BMs still have an adverse impact on survival and quality of life and the development...
[2]Miglietta F, Bottosso M, Griguolo G, et al. Major advancements in metastatic breast cancer treatment: when expanding options means prolonging survival. ESMO Open. 2022;7(2):100409. [3]Agostinetto E, Curigliano G, Piccart M. Emerging treatments in HER2-positive advanced breast cancer:...
FDA Approves Dato-DXd in HR+, HER2- Breast Cancer Following TROPION-Breast01 Effective and Well-Tolerated Combo in ER+/HER2– Metastatic Breast Cancer Kaklamani on Elacestrant for CDK4/6 Inhibitor-Naive ER+ Breast Cancer Treatment T-DXd in ER+/HER2-Low Breast Cancer: Insights From DESTINY...
Patients responding to one form of hormonal treatment had a greater likelihood of responding to subsequent hormonal manipulations. Additive hormonal therapy may provide effective palliation in males with advanced breast cancer, and should be considered as a valid alternative to orchiectomy. 展开 ...
Targeting breast cancer through this vital oncogenic protein has been a major step towards improved patient outcomes. Today, several anti-HER2 agents are in clinical use including: the monoclonal antibodies trastuzumab and pertuzumab; the small molecule inhibitors lapatinib, neratinib, and tucatinib; and...
This article reviews the challenges and future options in the treatment of ErbB2- positive metastatic breast cancer. It summarizes a presentation from a symposium that was held at the ECCO 14 congress in 2007. Despite great progress in the management of ErbB2-positive metastatic breast cancer, si...
Over the past 2 decades, there has been an extraordinary progress in the regimens developed for the treatment of human epidermal growth factor receptor 2 (HER2)-positive breast cancer. Trastuzumab, pertuzumab, lapatinib, and ado-trastuzumab emtansine (T-